Laminin a5 is a component of essentially all basement membranes in the kidney. It is particularly important in the glomerular basement membrane (GBM), where we have shown that it is necessary for maintenance of GBM integrity, for vascularization of glomeruli, and for mesangial cell organization of glomerular capillary loops. During the course of generating a conditional, floxed LamaS allele, we have serendipitously created a new mouse model for autosomal recessive polycystic kidney disease. This stems from the insertion of a FRT-flanked PGKneo selectable marker into an intron of LamaS, thus generating a hypomorphic LamaS allele, which we call LamaSneo. Preliminary studies show that LamaSneo/neo mice die at ~23 days of age with multiple large cysts, proteinuria, hematuria, and reduced levels of laminin a5 in most kidney basement membranes. Evidence that cysts are forming can be detected as early as the time of birth. The purpose of this limited two year Pilot and Feasibility Study is to segregate the putative epithelial cell/matrix defects in the tubular compartment of the nephron that result in cystogenesis, from the GBM defects that likely exacerbate kidney damage and speed the onset of renal failure in LamaSneo/neo mice. This will allow for a more meaningful analysis of cystogenesis and testing of hypotheses as to its origin. We will accomplish this by generating new transgenic mice that express the enhanced FLP recombinase specifically in podocytes, using the 2.5 kilobase podocin promoter. The FRT sites flanking the PGKneo are substrates for FLP recombinase, which will splice them together and delete the intervening PGKneo insertion specifically; in podocytes, thus restoring normal levels of laminin alphas in the GBM. We hypothesize this will also restore the integrity of the glomerular filtration barrier and allow a focused study of tubule defects that result in cystogenesis. In addition, the transgenic mice we will generate will serve as a useful resource to the nephrology research community, as they will provide a unique additional tool for manipulating podocyte gene expression. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21DK074613-02
Application #
7230078
Study Section
Special Emphasis Panel (ZRG1-RUS-B (02))
Program Officer
Rasooly, Rebekah S
Project Start
2006-04-04
Project End
2010-03-31
Budget Start
2007-04-01
Budget End
2010-03-31
Support Year
2
Fiscal Year
2007
Total Cost
$147,713
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Chen, Ying Maggie; Kikkawa, Yamato; Miner, Jeffrey H (2011) A missense LAMB2 mutation causes congenital nephrotic syndrome by impairing laminin secretion. J Am Soc Nephrol 22:849-58
Jarad, George; Pippin, Jeffrey W; Shankland, Stuart J et al. (2011) Dystroglycan does not contribute significantly to kidney development or function, in health or after injury. Am J Physiol Renal Physiol 300:F811-20
Goldberg, Seth; Adair-Kirk, Tracy L; Senior, Robert M et al. (2010) Maintenance of glomerular filtration barrier integrity requires laminin alpha5. J Am Soc Nephrol 21:579-86
Miner, Jeffrey H (2009) The amphibian kidney's filtration barrier: where is the glomerular basement membrane? Am J Physiol Renal Physiol 297:F549-50; author reply F551
Jarad, George; Miner, Jeffrey H (2009) Albuminuria, wherefore art thou? J Am Soc Nephrol 20:455-7
Jarad, George; Miner, Jeffrey H (2009) Update on the glomerular filtration barrier. Curr Opin Nephrol Hypertens 18:226-32
Miner, Jeffrey H (2008) Glomerular filtration: the charge debate charges ahead. Kidney Int 74:259-61